RLAY
Price
$8.67
Change
+$1.89 (+27.88%)
Updated
Feb 3 closing price
Capitalization
1.5B
15 days until earnings call
Intraday BUY SELL Signals
TARS
Price
$66.86
Change
-$3.52 (-5.00%)
Updated
Feb 3 closing price
Capitalization
2.84B
40 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RLAY vs TARS

Header iconRLAY vs TARS Comparison
Open Charts RLAY vs TARSBanner chart's image
Relay Therapeutics
Price$8.67
Change+$1.89 (+27.88%)
Volume$5.96M
Capitalization1.5B
Tarsus Pharmaceuticals
Price$66.86
Change-$3.52 (-5.00%)
Volume$650.38K
Capitalization2.84B
RLAY vs TARS Comparison Chart in %
RLAY
Daily Signal:
Gain/Loss:
TARS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
RLAY vs. TARS commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RLAY is a StrongBuy and TARS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (RLAY: $8.67 vs. TARS: $66.86)
Brand notoriety: RLAY and TARS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RLAY: 263% vs. TARS: 110%
Market capitalization -- RLAY: $1.5B vs. TARS: $2.84B
RLAY [@Biotechnology] is valued at $1.5B. TARS’s [@Biotechnology] market capitalization is $2.84B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RLAY’s FA Score shows that 1 FA rating(s) are green whileTARS’s FA Score has 0 green FA rating(s).

  • RLAY’s FA Score: 1 green, 4 red.
  • TARS’s FA Score: 0 green, 5 red.
According to our system of comparison, RLAY is a better buy in the long-term than TARS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RLAY’s TA Score shows that 5 TA indicator(s) are bullish while TARS’s TA Score has 4 bullish TA indicator(s).

  • RLAY’s TA Score: 5 bullish, 4 bearish.
  • TARS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, RLAY is a better buy in the short-term than TARS.

Price Growth

RLAY (@Biotechnology) experienced а +2.00% price change this week, while TARS (@Biotechnology) price change was -1.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.22%. For the same industry, the average monthly price growth was +3.03%, and the average quarterly price growth was +35.17%.

Reported Earning Dates

RLAY is expected to report earnings on Feb 19, 2026.

TARS is expected to report earnings on Mar 16, 2026.

Industries' Descriptions

@Biotechnology (-4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TARS($2.84B) has a higher market cap than RLAY($1.5B). RLAY YTD gains are higher at: 2.482 vs. TARS (-18.344). TARS has higher annual earnings (EBITDA): -70.9M vs. RLAY (-322.8M). RLAY has more cash in the bank: 596M vs. TARS (402M). RLAY has less debt than TARS: RLAY (33.3M) vs TARS (72.4M). TARS has higher revenues than RLAY: TARS (366M) vs RLAY (8.36M).
RLAYTARSRLAY / TARS
Capitalization1.5B2.84B53%
EBITDA-322.8M-70.9M455%
Gain YTD2.482-18.344-14%
P/E RatioN/AN/A-
Revenue8.36M366M2%
Total Cash596M402M148%
Total Debt33.3M72.4M46%
TECHNICAL ANALYSIS
Technical Analysis
RLAYTARS
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
88%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
81%
Declines
ODDS (%)
Bearish Trend 20 days ago
89%
Bearish Trend 10 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
74%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
RLAY
Daily Signal:
Gain/Loss:
TARS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NBSRX58.151.01
+1.77%
Neuberger Quality Equity Inv
CGRCX30.150.01
+0.03%
Invesco Comstock Select C
FTHFX53.15N/A
N/A
FullerThaler Behavioral Sm-Cp Eq R6
AMGAX17.69-0.14
-0.79%
Alger Mid Cap Growth A
FLRAX43.43-0.47
-1.07%
Nuveen Large Cap Select A

RLAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, RLAY has been loosely correlated with BDTX. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if RLAY jumps, then BDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLAY
1D Price
Change %
RLAY100%
+6.38%
BDTX - RLAY
55%
Loosely correlated
-0.79%
NRIX - RLAY
55%
Loosely correlated
-1.76%
IMNM - RLAY
52%
Loosely correlated
+3.18%
IMTX - RLAY
50%
Loosely correlated
-0.40%
NUVL - RLAY
50%
Loosely correlated
+2.12%
More

TARS and

Correlation & Price change

A.I.dvisor indicates that over the last year, TARS has been loosely correlated with XENE. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if TARS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TARS
1D Price
Change %
TARS100%
+1.41%
XENE - TARS
39%
Loosely correlated
+1.62%
ERAS - TARS
38%
Loosely correlated
-0.24%
RYTM - TARS
38%
Loosely correlated
-0.64%
RLAY - TARS
38%
Loosely correlated
+6.38%
XERS - TARS
36%
Loosely correlated
-0.27%
More